Señales en vivo de MTNB | Maximiza tus Ganancias con Getagraph.com

Live Chart Being Loaded With Signals

Commentary (26 abr 2024 @ 16:00):

Stats
Volumen de hoy	1.48M
Volumen promedio	1.58M
Capitalización de mercado	44.87M
EPS	$0 ( 2024-03-27 )
Próxima fecha de ganancias	( $-0.0300 ) 2024-05-08
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-1.630
ATR14	$0 (0.00%)

Insider Trading

Date	Person	Action	Amount	type
2023-12-15	Matkovits Theresa	Buy	1 300 000	Stock Option (right to Buy)
2023-12-15	Hoover Thomas	Buy	1 000 000	Stock Option (right to Buy)
2023-12-15	Kucinski Keith A	Buy	1 000 000	Stock Option (right to Buy)
2023-12-15	Liu Hui	Buy	1 000 000	Stock Option (right to Buy)
2023-12-15	Jabbour Jerome D	Buy	3 500 000	Stock Option (right to Buy)

INSIDER POWER
97.71
Last 97 transactions
Buy: 33 257 124 \| Sell: 4 123 116

Volumen Correlación

Largo: -0.20 (neutral)

Corto: -0.09 (neutral)

Signal:(42.12) Neutral

Matinas BioPharma Correlación

10 Correlaciones Más Positivas

10 Correlaciones Más Negativas

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Matinas BioPharma Correlación - Moneda/Commodity

0.53
( weak )

0.46
( neutral )

0.00
( neutral )

-0.51
( weak negative )

Matinas BioPharma Finanzas

Annual	2023
Ingresos:	$1.10M
Beneficio Bruto:	$155 000 (14.14 %)
EPS:	$-0.110

FY	2023
Ingresos:	$1.10M
Beneficio Bruto:	$155 000 (14.14 %)
EPS:	$-0.110

FY	2022
Ingresos:	$3.19M
Beneficio Bruto:	$-13.49M (-423.15 %)
EPS:	$-0.0600

FY	2021
Ingresos:	$33.00
Beneficio Bruto:	$0.00 (0.00 %)
EPS:	$-0.110

Financial Reports:

No articles found.

Matinas BioPharma

Matinas BioPharma Holdings, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of various product candidates. It develops products using its lipid nanocrystal (LNC) platform technology. The company's LNC delivery technology platform utilizes lipid nano-crystals for the delivery of small molecules, nucleic acids, gene therapies, vaccines, proteins, and peptides. Its lead product candidate is LYPDISO, a prescription-only omega-3 free fatty acid-based composition intended for the treatment of cardiovascular and metabolic conditions. The company also offers MAT2203, an oral formulation of amphotericin B that is in Phase II clinical trials for the prevention of invasive fungal infections due to immunosuppressive therapy in patients. In addition, it provides MAT2501, an orally administered formulation of the broad-spectrum aminoglycoside antibiotic amikacin that has completed Phase I clinical trials to treat various types of multidrug-resistant bacteria, including non-tuberculous mycobacterium infections, as well as various multidrug-resistant gram negative and intracellular bacterial infections. Matinas BioPharma Holdings, Inc. has a research collaboration with the National Institute of Allergy and Infectious Diseases for the development of Gilead's antiviral remdesivir; and a feasibility collaboration with Genentech, Inc. for the development of oral formulations. The company was incorporated in 2013 and is based in Bedminster, New Jersey.